EirGenix Inc. (6589.TWO)

TWD 73.1

(-1.88%)

Market Cap (In TWD)

22.28 Billion

Revenue (In TWD)

1.02 Billion

Net Income (In TWD)

-915.2 Million

Avg. Volume

952.17 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
66.9-103.0
PE
-
EPS
-
Beta Value
0.614
ISIN
TW0006589005
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Lee-Cheng Liu
Employee Count
-
Website
https://www.eirgenix.com
Ipo Date
2016-11-23
Details
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. EirGenix Inc. was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.